Epsilon Healthcare Limited (ASX:EPN) entered into binding heads of agreement to acquire AlternaMed Pty Ltd. from Cannvalate PTY LTD for AUD 4.3 million on September 9, 2021. Under the terms of the transaction, Epsilon Healthcare Limited will issue 28.9 million fully paid shares to acquire AlternaMed. Epsilon Healthcare Limited will acquire AlternaMed including its portfolio of intellectual property relating to three novel cannabinoid therapeutic agents with a view to Schedule 3 medicines production. The transaction is subject to signing of definitive agreement, Epsilon Healthcare Limited taking any regulatory or shareholder approvals as required. Cannvalate has agreed to a holding lock on the Consideration Shares for a period of twelve months from the date of issue of the Consideration Shares.